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Vigabatrin (VGB) is a novel antiepileptic drug which inhibits GABA-transaminase (GABA-T) and thus increases the level of
GABA in the CNS and in its neurons. In the last few years, evidence has been presented that VGB intake may be associated
with concentric visual field restrictions. The aim of this study was to estimate the prevalence of visual field constrictions
and to determine if, and to what extent, they depend on the duration of VGB treatment. Visual fields of 15 patients who were
taking VGB, and 12 matched control patients who had never been exposed to VGB, were investigated using a kinetic Goldmann
perimeter. One of the 12 matched control patients had a slightly restricted visual field whereas nine of the 15 VGB patients (60%)
showed a moderate to severe concentric visual field restriction. The extent of the outer isopters (V4, I4, I3, I2) depended on
the duration of VGB intake. VGB treatment was clearly associated with a high prevalence of concentric visual field restriction.
Moreover, the degree of visual field restriction depended on the duration of VGB intake. Further work, including longitudinal
studies, is needed to clarify whether these lesions are reversible or not.
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INTRODUCTION
Vigabatrin (VGB) is an irreversible inhibitor of
GABA-transaminase (GABA-T) and thereby in-
creases the level of the major inhibitory neurotrans-
mitter GABA. After Eke et al.1 reported three patients
with concentric visual field losses following VGB
therapy, several studies showed visual field constric-
tion during VGB therapy. In 1999, Hoechst Marion
Roussel reported the overall prevalence to be up to
28% with a 95% confidence interval between 20%
and 36%2. In 1999, Lawden, Eke, Degg and col-
leagues3 presented a study which investigated 33 VGB
patients and 16 controls with static perimetry, elec-
trooculograms, electroretinograms and visual evoked
responses. Twelve (39%) of the 31 VGB patients had a
definite bilateral field defect with temporal and macu-
lar sparing and none of the 16 control patients showed
any visual field losses. In a study by Ka¨lvia¨inen et al.4,
13 of 32 VGB patients (41%) had concentric visual
field defects but there was only weak correlation be-
tween the duration of VGB therapy and the extent
of visual field defects in both eyes. Another study
by Miller et al.5 with 39 VGB patients revealed that
nearly 50% had constricted visual fields.
PATIENTS AND METHODS
Seventeen patients who were taking or who had previ-
ous exposure to VGB therapy and 12 control patients,
all attending the Department of Neurology at the Uni-
versity Hospital of Zurich, were identified and in-
vestigated by a manual kinetic Goldmann perimeter
(Haag-Streit, Bern, Switzerland). Two patients from
the VGB group had to be excluded because they both
had homonymous hemianopsia. Fifteen VGB patients
and 12 control patients remained. At the time of the in-
vestigation, the investigator was aware of which group
the patients belonged to. All 27 patients were suffering
from a partial epilepsy with simple partial or complex
partial seizures, a few with occasional secondary gen-
eralization. The patients on VGB therapy were cho-
sen at random. The patients for the control group were
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chosen to match in age, concomitant medication, his-
tory of seizures and history of relevant operations. As
the epilepsy unit of the University Hospital Zurich is a
referral centre for epilepsy surgery in patients suffer-
ing from a partial epilepsy, most of the patients have
a history of a selective amygdalo-hippocampectomy
(AHE)6. This operation can cause homonymous con-
tralateral upper quadrant defects.
For analysis of the Goldmann perimetry, we mea-
sured the temporal, superior, nasal and inferior range
of each isopter (V4, I4, I3, I2, I1) of both eyes sepa-
rately. In addition, the mean extent of each isopter was
obtained by measuring the radial extent at 12 points
of the visual field, 30 degrees apart. The mean vi-
sual field extents were calculated by averaging each
of these 12 points.
Statistical analysis was done with SPSS for
Windows 9.0 (Mann–Whitney test corrected for
ties, Fisher’s exact test, one-way analysis of vari-
ance (ANOVA), repeated measures ANOVA with
Greenhouse-Geisser’s correction, Pearson correla-
tion). The significance level was fixed to be α = 0.05.
In certain analyses, Bonferroni’s correction was used,
which is defined as follows: let k denote the number of
performed tests, then the corrected significance level
α∗ is computed as α∗ = α/k.
RESULTS
The age of the patients ranged from 13 to 52 years in
the VGB group and from 12 to 52 years in the control
group. (Mann–Whitney test, P = 0.45). There were
seven men and five women in the control group and
nine men and six women in the VGB group (Fisher’s
exact test, P = 1.00). From the 15 VGB patients, one
had simple partial seizures, 11 had complex partial
seizures and three suffered from occasional secondary
generalization. Among the 12 control patients, there
were three with simple partial, six with complex par-
tial seizures and three suffering from secondary gener-
alization.
Only five of the 15 VGB patients were taking VGB
on a daily basis at the time of the evaluation. Of those,
four were taking 2 g and one was taking 2.5 g per day.
The remaining ten patients had stopped taking the drug
7–48 months previously. In these cases, the drug was
withdrawn mostly because of a general reduction in
antiepileptic drug (AED) regimen, and in a few cases
because of ineffectiveness. In none of the patients was
VGB discontinued because of any visual symptoms.
Mean length of treatment with VGB was 47.2 months,
ranging from 13 to 94 months and the daily dose taken
during this time was either 2 g or 2.5 g. Thus, the total
amount of VGB taken ranged from 780 g to 5640 g
(mean 3062 g).
Table 1: Extent of visual fields in VGB and control patients
(V4 object).
Meridian Control (n = 12) VGB (n = 15)
Temporal 86.8 ± 4.5 69.2± 13.0a
Superior 45.3 ± 5.2 41.9± 7.6a
Nasal 56.3 ± 4.3 46.8± 9.5a
Inferior 68.3 ± 5.3 57.0± 12.7a
Mean 63.3 ± 2.7 53.8± 9.6a
Data presented is the mean extent ± SD.
a Significant at the 0.05 level compared with control
(Mann–Whitney test).
Eleven patients were taking other AEDs in addi-
tion to VGB. Of these 11 patients, eight were also
taking carbazepine. Other drugs frequently taken by
these patients were valproate and phenytoin. The AED
regimen also included clobazam, lamotrigine, pheno-
barbital, topiramate, ethosuximide. Among the control
patients carbazepine, valproate and phenytoin were the
most commonly used AED.
Ten of the 15 VGB patients had undergone a selec-
tive AHE before the perimetry was performed. One
had had a parietal operation on the right side. Of the
nine control patients, eight had undergone a selective
AHE. Among the patients in the VGB group, 14 had
no subjective visual problems. One was bumping into
objects quite frequently. None of the control patients
complained about visual problems. The minimal vi-
sual field restriction in the superior part of the visual
field, which can result from a selective AHE, was not
noticed by any of the patients.
In order to estimate how much the mean visual field
extent of the VGB patients differs from the mean vi-
sual field extent of the control patients, a repeated
measures ANOVA with the Greenhouse-Geisser cor-
rection was carried out. There was a significant differ-
ence between the VGB group and the control group.
The VGB patients had narrower isopters than the con-
trol patients (P = 0.015). Post hoc analysis with Bon-
ferroni’s correction was performed. The mean extent
of each isopter was compared to the control group.
Only mean visual field extents of the V4 object dif-
fered significantly (α∗ = 0.01; Mann–Whitney test,
P = 0.009) whereas mean visual field extents for the
other isopters did not differ significantly (α∗ = 0.01;
I4, P = 0.013; I3, P = 0.083; I2, P = 0.222; I1,
P = 0.922). Thus, the outermost part of the visual
field was the most affected part.
The mean extent of the visual field and each of
the four meridians, obtained when using the V4 ob-
ject of the perimeter, were analysed separately (Ta-
ble 1). There were significant differences between the
two groups for the mean extent (P = 0.007) and for
the four meridians (temporal, P = 0.000; superior,
P = 0.236; nasal, P = 0.014; inferior, P = 0.012).
Figure 1 shows the mean visual field extent in both
collectives.
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Fig. 1: Mean visual field extent∗ (V4 object).
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Fig. 2: Dependence of the mean visual field extent on the
duration of VGB intake. The mean visual field extent (V4
object) depends on the duration of the VGB intake. Linear
regression with a 95% prediction interval is presented.
Mean visual extent = 67.08− 0.28× VGB intake (months).
R-square = 0.50.
To estimate if the visual field restriction depends
on the duration of VGB intake, only data from the
VGB collective were taken into consideration. A re-
peated measures ANOVA with covariate (duration of
VGB intake) was carried out. There was a significant
decrease of the visual field extents of all isopters ac-
cording to the duration of VGB intake (B = −0.24,
P = 0.006). Each isopter was tested individually.
There was a high significance for V4, I4, I3 and I2
isopters (α∗ = 0.01; V4, B = −0.28, P = 0.003; I4,
B = −0.30, P = 0.006; I3, B = −0.30, P = 0.003;
I2, B = −0.259, P = 0.010). However, the innermost
isopter did not show a significant dependence on the
duration of drug intake (α∗ = 0.01; I1, B = −0.071,
P = 0.309). The dependence of the mean visual field
extent on the duration of VGB intake is shown in
Fig. 2.
DISCUSSION
The results of the prospective cross-sectional study
suggest that VGB treatment is associated with con-
centric visual field restriction. Furthermore, this study
shows that the degree of visual field loss depends on
the duration of VGB intake.
Most of the patients in the VGB group had narrowed
isopters in comparison to the control patients. This ef-
fect was most obvious in the outermost (V4) isopter
and less obvious in the inner isopters (I4, I3, I2). There
was no difference between the two collectives in the
innermost isopter (I1). Thus VGB leads not only to a
concentric visual field restriction but also to a diffuse
decreased sensitivity in the inner parts of the visual
field. As the results from the V4 isopter shows, the
temporal and the inferior meridian were the most af-
fected parts.
In this study, nine (60%) of the 15 examined VGB
patients had concentric visual field restriction with a
mean visual field extent ranging from 37 to 54.5 de-
grees. The other six VGB patients had a mean vi-
sual field extent of 60 degrees or more. Eleven of the
12 control patients had a mean visual field extent of
60 degrees or more, and one had a mean visual field
extent of 56.5 degrees. The visual field constriction
which was detected by kinetic perimetry was asymp-
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tomatic in all patients except for one. Only one patient
in the VGB group complained about bumping into ob-
jects frequently.
There was a strong dependence of the degree of the
visual field restriction and the duration of VGB med-
ication. All but the innermost isopter were more nar-
rowed when the duration of VGB intake increased. In
this study, the visual field showed an average restric-
tion of each isopter of about 3–4 degrees per year of
VGB intake.
This study has limitations. First, the number of
patients examined was relatively small. However, the
statistical analysis was carried out carefully and Bon-
ferroni’s correction was used where necessary. Sec-
ond, most of the patients in the VGB and in the
control group had undergone a selective amygdalo-
hippocampectomy, which can reduce visual field in the
sense of an upper homonymous quadrantanopsia.
Thus far, two cases with an improvement of vi-
sual field constriction after the discontinuation of VGB
have been described by Krakow and colleagues7. This
suggests that vigabatrin-associated retinal changes
may be at least partly reversible in some patients af-
ter the drug has been discontinued. In another study,
the visual fields of 13 patients who stopped taking
VGB were not improved after several months of with-
drawal8. Research is needed to clarify the mechanism
of the concentric visual field restrictions which oc-
cur under VGB treatment. Longitudinal section studies
could help to determine if and to what extent there is
reversibility. Baseline visual field testing before VGB
is administered allows the determination of the exact
extent of visual field losses.
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